SARASOTA, FL, April 10, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical...
On April 16th, moderator David Rahn of Psy-Ins will sit with ketamine providers that have built or are currently building their ketamine companies. During...
MORRISTOWN, N.J., April 03, 2024 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to...
VANCOUVER, British Columbia, April 03, 2024 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF /...
TORONTO, March 27, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology...
NEW YORK and BERLIN, March 28, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”) a clinical-stage biopharmaceutical...
Recent studies have unearthed fascinating insights into how psilocybin, a naturally occurring compound in certain mushroom species—often referred to...
Recent studies have shed light on the intriguing potential of hallucinogenic mushrooms, specifically those containing psilocybin, in offering therapeutic...
VANCOUVER, BC, March 20, 2024 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company“) (TSX: NUMI) (OTCQX: NUMIF), a mental health care...
SARASOTA, FL, March 20, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical...